Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Digital Biomarkers

Editorial Board


E. Ray Dorsey – University of Rochester, Rochester, USA

Dr. Ray Dorsey is the David M. Levy Professor of Neurology and Director of CHET, a center that seeks to advance knowledge and improve health through ground-breaking research, at the University of Rochester Medical Center. Through novel applications of technology, he and his colleagues seek to enable anyone anywhere to receive care, participate in research, and benefit from therapeutic advances.

Dr. Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins and worked as a consultant for McKinsey & Company. Dr. Dorsey’s research has been published in leading medical, neurology, and economic journals and has been featured on National Public Radio and in The New York Times and The Wall Street Journal. In 2015 he was recognized as a White House “Champion for Change” for Parkinson’s disease.

Section Editor 'Network of Digital Evidence (NODE)'

Ashish Atreja – Icahn School of Medicine at Mount Sinai, New York, USA

Dr. Atreja has received formal training in public health and is board certified in gastroenterology, clinical informatics and internal medicine. Over the last fifteen years, he has led many public health and informatics initiatives at Cleveland Clinic and Mount Sinai Medical Center, NY that includes developing online education modules, leading EHR implementation, performing analytics on healthcare data and developing enterprise-wide mobile apps. As Chief Technology Innovation and Engagement Officer, Medicine, he leads the Sinai AppLab that is one of the first collaborative hub within academic medical center to build and test disruptive mhealth technologies.
Dr. Atreja leads scientific registries for American Gastroenterology Association and serves in Innovation Advisory Board for American College of Cardiology. As an intrapreneur, Dr. Atreja has won innovation awards at Cleveland Clinic and Mount Sinai, successfully licensed technologies from academic centers and advises startups, accelerators and Fortune 500 companies in digital medicine. Recently, Dr. Atreja established Network of Digital Medicine to connect innovation centers worldwide and share best practices for digital medicine innovation and implementation between industry, payers and health systems. Dr. Atreja serves as Scientific Co-founder for Mount Sinai Spinoff, Responsive Health that aims to bring first enterprise-wide app curation, prescription and engagement platform to risk sharing hospitals and payers. Dr. Atreja has published more than 60 papers and has been a keynote speaker globally on topics related to digital medicine and health system transformation.

Advisory Board

Mark Frasier – The Michael J. Fox Foundation for Parkinson's Research, New York, USA

As Senior Vice President, Research Programs, Mark co-manages a team of research professionals who stay closely linked to the Parkinson’s research community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson’s disease. This ensures that MJFF research priorities reflect and best serve the ultimate needs of patients. Mark regularly meets with academic and industry researchers around the world to identify promising proposals to support, providing troubleshooting and ongoing management of projects as they go forward. He also supports the Foundation’s priority interest in developing biomarkers for Parkinson’s disease that will accelerate clinical trials of new drugs.

Dr. Frasier earned an undergraduate degree in Biochemistry from the University of Dayton and a PhD in Pharmacology from Loyola University Chicago. He completed his postdoctoral work in the Neuroscience Discovery Research Group at Eli Lilly, Inc., in Indianapolis, Indiana, where he worked on drug-discovery research in Parkinson's and Alzheimer's disease. Since joining MJFF in 2006 he has led innovative strategies to support Parkinson’s therapeutic development and address pre-clinical, clinical, and regulatory challenges.

Ernst Hafen – ETH, Zurich, Switzerland

Ernst Hafen obtained his PhD from the Biocenter at the University of Basel in 1983. From 1984 to 1986 he worked at the University of California in Berkeley as a postdoctoral fellow before joining the University of Zurich as an assistant professor in 1987. He was promoted to full professor in 1997. From 2005 to 2006 he served as president of ETH Zurich. Since 2005 he holds a professorship at the Institute of Molecular Systems Biology at ETH Zurich.

(EB) p_heldt
Thomas Heldt – Massachusetts Institute of Technology, Cambridge, USA

Thomas Heldt holds the W.M. Keck Career Development Chair in Biomedical Engineering at the Massachusetts Institute of Technology (MIT), where he is also an Associate Professor of Electrical and Biomedical Engineering, a core faculty member of the Institute for Medical Engineering & Science, and a Principal Investigator with the Research Laboratory of Electronics. In addition, he is a member of the Affiliate Faculty at Harvard Medical School. Prof. Heldt studied Physics at Johannes Gutenberg University, Germany, Yale University, and MIT. He received his PhD in Medical Physics from the Harvard-MIT Division of Health Sciences and Technology and commenced postdoctoral training at MIT's Laboratory for Electromagnetic and Electronic Systems.

Prof. Heldt's research interests focus on signal processing, mathematical modelling, and model-identification to support real-time clinical decision making, monitoring of disease progression, and titration of therapy in a variety of patient-care settings. In particular, Prof. Heldt's research focuses on developing a mechanistic understanding of physiologic systems, and in formulating appropriately chosen computational physiologic models for improved patient care.

Prior to joining the Advisory Board of Digital Biomarkers, Prof. Heldt served as Associate Scientific Advisor to Science Translational Medicine. He chairs the Cardiopulmonary Systems Technical Committee of the IEEE Engineering in Medicine and Biology Society (EMBS) and has served as an Associate Editor of the annual EMBS conference since 2011.

John D. Hixson – University of California, San Francisco, San Francisco, USA

I'm currently a faculty member in the Dept of Neurology at both UCSF and the SF VA Medical Center. I primarily treat epilepsy patients, but am also developing several projects exploring the use of mobile health applications to improve the longitudinal care of patients with chronic disease. More specifically, I am interested in conducting clinical trials utilizing mobile health technologies (online diary systems and databases, electronic pillboxes) to improve clinical outcomes and cost efficiency. I am a part of the UCSF mHealth Group and the VA Innovations Initiative Patient-Facing Effort.

Dan Karlin – Pfizer, Cambridge, USA

Dr Karlin is a board certified psychiatrist and medical informatician working at the intersection of health and technology in the pharmaceutical industry on novel data and analysis driven strategies for neuropharmaceutical development and in academic medicine where he practices psychiatry, provides clinical care, teaches clinical skills and quality improvement, and helps run a residency program. He is also involved in medical technology and care delivery startups and serve in medical director and advisor roles for these companies. In this context he has invented and contributed to the creation of novel medical devices. Of particular interest is the study of human cognition across the spectrum of healthcare, assessing decision-making strategies used in these environments and the ways in which technology and other tools impact these strategies and the consequent decisions. Prior to training as a physician, Dr Karlin managed emergency medical services systems and disaster response including the early stages of the rescue effort at the World Trade Center collapse.

Joseph Kvedar – Harvard Medical School, Boston, USA

Joseph Kvedar, MD, is a board-certified dermatologist and Associate Professor of Dermatology at Harvard Medical School. He is also the Founder and Director of the Center for Connected Health, where he is creating a new model of healthcare delivery, and developing innovative strategies to move care from the hospital or doctor's office into the day-to-day lives of patients.

Dr. Kvedar established the first physician-to-physician online consultation service in an academic setting, linking patients from around the world with specialists at Harvard-affiliated teaching hospitals.

He is internationally recognized for his leadership and vision in the field of connected health, and has authored over 90 publications on the subject. Dr. Kvedar serves as a Board member for a number of organizations, including Care Continuum Alliance. He serves as a strategic advisor at West Health Institute, and is a mentor at Blueprint Health and Rock Health, providing guidance and insight to developing companies.

Max Little – Aston University, Birmingham, UK

I began my career writing software, signal processing algorithms and music for video games, then moved on by way of a degree in mathematics to the University of Oxford. After postdoc positions in Oxford and co-founding a web-based image search business, I won a Wellcome Trust fellowship at MIT to follow up on my doctoral research work in biomedical signal processing. I am currently a Senior Lecturer (Associate Professor) at Aston University in the UK.

Kenneth D. Mandl – Harvard Medical School, Boston, USA

Mandl's work at the intersection of population and individual health has had a unique, sustained influence on the developing field of biomedical informatics. Mandl has long advocated for patient participation in producing and accessing data. He created the first personal health systems, crowdsourced knowledge from online patient networks, and advanced participatory medicine and engagement in clinical trials. Cognizant of the limitations of extant electronic health record systems, Mandl developed a widely adopted, highly influential approach (SMART) – substitutable iPHone-like apps that run universally on health IT systems. He was advisor to two Directors of the CDC and chaired the Board of Scientific Counselors of the NIH’s National Library of Medicine. Dr. Mandl has been elected to multiple honor societies including the American Society for Clinical Investigation, Society for Pediatric Research, American College of Medical Informatics and American Pediatric Society. He is a recent recipient of the Donald A.B. Lindberg Award for Innovation in Informatics.

William J. Marks, Jr. – Verily Life Sciences, San Francisco, USA

Dr. William Marks is Head of Clinical Neurology at Verily Life Sciences (an Alphabet company, formerly Google Life Sciences), a translational research and engineering organization focused on improving healthcare by applying scientific and technological advances to significant problems in health and biology. Dr. Marks is responsible for developing and implementing strategies and initiatives that will advance the understanding of neurological disorders to ultimately improve patient outcomes. He is also Adjunct Clinical Professor of Neurology and Neurological Sciences at Stanford University School of Medicine. Previously, Dr. Marks served as Professor of Neurology at the University of California, San Francisco (UCSF). He received his medical degree from the Johns Hopkins University School of Medicine and completed his neurology residency and fellowship at UCSF. Dr. Marks also holds a Master of Science in Health Care Management degree from the Harvard School of Public Health.

Michael Rebhan – Novartis, Basel, Switzerland

Dr. Michael Rebhan (Ph.D.) is a scientist in the life science industry, working on applied research. He is interested in enabling teams in pioneering spaces, to answer translational questions related to human disease, across institutions and disciplines. As a Senior Investigator at the ‪Novartis Institutes for BioMedical Research‬‬‬‬ in Basel (Switzerland, since 2008), he has been working on problems in a variety of non-Oncology indications, with a focus on Regenerative Medicine. This involves the generation of longitudinal, human multichannel data to inform our understanding of biomarkers, human diversity in disease, disease progression stages and related pathobiology. Enabling a better integration of therapies, diagnostics and digital tools around the patient journey, in a more collaborative and more outcomes-centric health innovation ecosystem, is a long-term interest. --- After a Masters in biology (1993), he did a PhD (1996) investigating fundamental aspects of disease progression and biology at a cellular level, before doing a postdoc in bioinformatics, as omics profiling technologies were entering biomedical research. During the postdoc, he developed the first versions of GeneCards at the Weizmann Institute (1996-1998), a bioinformatics platform that integrates information on human genes. Before coming to Basel in 2004, he worked on building bioinformatics capabilities in Singapore (A*STAR, Biopolis, Bioinformatics Institute, 2002-2004), Boston (AstraZeneca R&D center, 1998-2000) and other places (a biotech startup in Germany, Lion Bioscience, 2000-2002). This includes exposure to connected fields like the biology of disease, data-intensive technologies, user-centric system design, IT infrastructure, biomedical R&D pipelines, digital health technology, biomedical big data, drug discovery problems, and community building in those areas. In 2004 he moved to Switzerland, and has stayed there since, to first join the FMI in Basel, before he joined NIBR (Novartis Research) in 2008. See also his profile on LinkedIn at https://ch.linkedin.com/in/michael-rebhan-b022751

Stefan Scherer – Novartis, East Hanover, USA

Torsten Schwede – University of Basel, Basel, Switzerland

John Wilbanks – Sage Bionetworks, Seattle, USA

John Wilbanks is the Chief Commons Officer at Sage Bionetworks. Previously, Wilbanks worked as a legislative aide to Congressman Fortney “Pete” Stark, served as the first assistant director at Harvard’s Berkman Center for Internet & Society, founded and led to acquisition the bioinformatics company Incellico, Inc., and was executive director of the Science Commons project at Creative Commons. In February 2013, in response to a We the People petition that was spearheaded by Wilbanks and signed by 65,000 people, the U.S. government announced a plan to open up taxpayer-funded research data and make it available for free. Wilbanks holds a B.A. in philosophy from Tulane University and also studied modern letters at the Sorbonne.

Editorial Board

Jitendra Barmecha – SBH Health System, New York, USA

Dr. Jitendra Barmecha began his clinical and healthcare leadership career at SBH Health System as Chief Medical Resident after completing three years in the Internal Medicine Residency Program. Following his chief medical residency, he earned his MPH degree in Health Management and Policy at New York Medical College, while continuing to provide patient care and medical education services as faculty in the Department of Medicine at St. Barnabas Hospital.
Presently, as Chief Information Officer and Senior Vice President of Information Technology, Health Care Data & Analytics and Clinical Engineering, is setting up the IT infrastructure for Population Health Management for his health system as one of the lead Provider Performing System (PPS) - DSRIP in the Bronx. His team has already completed the upgrade of electronic health records (EHR) to comply with Stage 2 Meaningful Use of EHR. He is also involved in upgrading the systems technical infrastructure; ensuring clinical information systems and patient monitoring devices are well integrated into the electronic health records for the future. As a board member and chair of the clinical committee, he provides clinical leadership to the Bronx Regional Health Information Exchange (RHIO) & Bronx Regional Informatics Center.
Dr. Barmecha serves on the advisory panel for the physician payment reforms and practice transformation at the American College of Physicians. He is a fellow of American College of Physician, Senior Fellow of Hospital Medicine and Fellow of New York Academy of Medicine. He is the past president and chairman of the Board of Bronx County Medical Society. While continuing his passion for bedside patient care as a hospitalist, he enjoys teaching clinical staff and medical students, and routinely provides lectures on health care management, technology and policy.

Kevin Biglan – Eli Lilly and Company, Indianapolis, USA

Dr. Kevin Biglan is a Neurologist trained in Movement Disorders and Experimental therapeutics. He was most recently Professor of Neurology and the Associate Chair of Clinical Research at the University of Rochester. In that role, he was actively involved in the development and validation of remote technologies to improve care and facilitate research in movement disorders. Since 2017, he has been involved in early phase clinical development in neurodegenerative diseases at Eli Lilly and Company. In this capacity he has been active in incorporating digital biomarkers into drug development in order to speed the development of drugs for those with the greatest need.

Bastiaan Bloem – Radboud University Medical Center, Nijmegen, Netherlands

Professor Bas Bloem is a consultant neurologist at the Dept of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. He received his M.D. degree (with honour) at Leiden University Medical Centre in 1993. In 1994, he obtained his PhD degree in Leiden, based on a thesis entitled “Postural reflexes in Parkinson’s disease”. He was trained as a neurologist between 1994–2000, also at Leiden University Medical Centre. He received additional training as movement disorders specialist during fellowships at ‘The Parkinson's Institute’, Sunnyvale, California (with Dr J.W. Langston), and at the Institute of Neurology, Queen Square, London (with Prof. N.P. Quinn and Prof. J.C. Rothwell). In 2002, he founded and became Medical Director of the Parkinson Centre Nijmegen (ParC), which was recognised from 2005 onwards as centre of excellence for Parkinson’s disease. Together with Dr. Marten Munneke, he also developed ParkinsonNet, an innovative healthcare concept that now consists of 66 professional networks for Parkinson patients covering all of the Netherlands (www.parkinsonnet.nl). Because of the evidence-based quality improvement and significant cost reduction, ParkinsonNet has received multiple awards, including the prize ‘Best Pearl for Healthcare Innovation’ in 2011 and ‘Value Based Health Care’ prize in 2015. In September 2008, he was appointed as Professor of Neurology, with movement disorders as special area of interest. Prof. Bloem has published over 550 publications, including over 400 peer-reviewed international papers. His H-index is 49.

Paolo Bonato – Harvard Medical School, Charlestown, USA

Paolo Bonato, Ph.D., serves as Director of the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital, Boston MA. He is an Associate Professor in the Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston MA, an Adjunct Professor of Biomedical Engineering at the MGH Institute of Health Professions, Boston MA, an Associate Faculty Member at the Wyss Institute for Biologically Inspired Engineering, and an Adjunct Professor of Electrical and Computer Engineering at Northeastern University. He has held Adjunct Faculty positions at MIT, the University of Ireland Galway, and the University of Melbourne. His research work is focused on the development of rehabilitation technologies with emphasis on wearable technology and robotics. He received the M.S. degree in electrical engineering from Politecnico di Torino, Turin, Italy in 1989 and the Ph.D. degree in biomedical engineering from Universita` di Roma “La Sapienza” in 1995. A list of his publications can be found here.

Ernst Jan Bos – Center for Human Drug Research, Leiden, Netherlands

Ernst Jan Bos graduated in Medicine from Leiden University. In between he worked at the Falk Cardiothoracic Research Department at Stanford Medical School under Prof Robert C Robbins for a year on cardiac regeneration. Subsequently he pursued a PhD at VU University Amsterdam Medical Center on 3D bio printing for facial cartilage reconstruction. During his PhD he quickly recognized the necessity to work with different disciplines and collaborated closely with the Technical University of Delft. The synapse between engineers and health professionals has been his main focus since and led to several spin-off projects in various fields, including haptic feedback and virtual simulation. He joined the Center for Human Drug Research in 2016 providing consultancy to pharmaceutical industries with special emphasis on technical innovation for clinical research trials, ranging from the development of eHealth applications to novel sensor technologies. As a mentor and guest lecturer on entrepreneurship in life science and health he is involved in various educational and accelerator initiatives.

(EB) p_Capobianco
Enrico Capobianco – University of Miami, Miami, USA

Enrico Capobianco is the Head of the Computational Biology and Bioinformatics program at the Center for Computational Science of the University of Miami, associated with the main campus and the Miller School of Medicine in Miami, FL, USA. He holds a Doctorate in Statistical Sciences from the University of Padua, in Italy. His core expertise is in Statistical Inference and Network Science, whereas his applications are especially in Systems Medicine approaches to Cancer and Digital Health. His most recent interests include Stochastics and Machine Learning methods for Big Data Analytics and Computational Imaging. Dr Capobianco has participated in academic and scientific activities at several US institutes, and received a Professorship from the Chinese Academy of Sciences in 2011, a Visiting Professorship in 2010 from the Fiocruz Foundation in Brazil, and was Visiting Scientist at the Institut des Hautes Études Scientifiques in France.

Ieuan Clay – Novartis, Basel, Switzerland

Throughout his career Ieuan Clay has focused on technology and analytics development; following his graduate work at Cambridge University in the field of Next Generation Sequencing, he joined Novartis in 2010 as part of early target discovery concentrating on novel assays, screening and profiling methods. This role evolved into piloting technology deployment in clinical settings, and after a short sabbatical in a startup company, he now leads the Digital Endpoints group within NIBR-Translational Medicine, developing novel analytics for sensor technologies to capture objective, functional readouts tailored to specific demographics and clinical questions.

Adam Cohen – The Johns Hopkins University Applied Physics Laboratory, Laurel, USA

Adam Cohen leads the Health Technologies program within the National Health Mission Area of Johns Hopkins University Applied Physics Laboratory. He is also a clinical neurologist at Johns Hopkins Hospital in Baltimore, Maryland, where he focuses on inpatient neurology. Prior to Hopkins, Adam was the Director of Inpatient Neurology and TeleNeurology at Massachusetts General Hospital in Boston, Massachusetts, where he cared for neuro-ophthalmology and inpatient neurology patients. Adam has worked with a number of additional entities to apply health technology to process innovation.

Jean-Philippe Couderc – University of Rochester, Rochester, USA

Dr. Couderc is a biomedical engineer who obtained his PhD degree with highest honors from the French National Institute of Applied Sciences in Lyon, France in 1997. He is Associate Professor of Medicine in the Cardiology Department of Strong Memorial Hospital (Rochester, NY) and Research Associate Professor of Electrical and Computer Engineering at University of Rochester (NY). He is leading the Telemetric and Holter ECG Warehouse initiative (THEW-project.org). Dr. Couderc is a principal investigator and a co-investigator in several federal-funded research grants involving the development of ECG and wearable technologies. In addition, he holds the position of Chief Technology Officer at iCardiac Technology Inc. a Rochester-based research spinoff delivering high-precision ECG-based safety and efficacy metrics to international pharmaceutical companies.
Dr. Couderc has been invited for lectures by universities in US and Europe and by private and national laboratories (NIH and EPA). He is currently holding a position of Special Governmental Employee at the Center for Drug Evaluation and Research (CDER) for the Food and Drug Administration of the US. Department of Health & Human Services. Currently, he has more than 80 publications and his work has been highlighted in The Wall Street Journal.

Martin Daumer – Sylvia Lawry Centre For Multiple Sclerosis Research, Munich, Germany

Dr. Martin Daumer is the Director of the SLCMSR e.v. – The Human Motion Institute in Munich and the managing director of the IT company, Trium Analysis Online GmbH. He is also a visiting lecturer for Telemedicine and Clinical Applications of Computational Medicine at the Technical University Munich.

Dr. Daumer received a diploma in Physics in 1990 and a Ph.D. in mathematics from the Ludwig-Maximilians-University Munich in 1995, after having worked at CERN, Switzerland, and Rutgers University, USA.

Adam P. Dicker – Thomas Jefferson University, Philadelphia, USA

Dr. Adam P. Dicker, MD, PhD is Senior Vice President, Professor and Chair, Department of Radiation Oncology at Sidney Kimmel Cancer Center at Thomas Jefferson University. He is a leading expert in prostate cancer and brain tumors with a focus on digital health and translational sciences applied to oncology.

Dr. Dicker leads a University-wide effort in Digital Health, using the convergence of mobile technology, platforms, networks, and machine learning to improve the lives of patients. His group created the first Apple ResearchKit app for patient reported outcomes (PROs) for prostate cancer patients “Strength Through Insight” and are conducting innovative, collaborative research to transform digital health into a standard part of modern cancer care relevant to the 21st century healthcare. Dr. Dicker’s current research is focused on collection of PROs and remote activity monitoring (i.e., Fitbit) for patient receiving chemo-radiation, molecular targeted therapies and immunotherapy.

His laboratory research coordinates an interdisciplinary team of oncologists, immunologists, physicists, data scientists and scientists participating in a multidisciplinary effort to define fundamental mechanisms and targets for cancer treatment and efficiently translate them to effective innovations for patients. His work has focused on how ionizing radiation can enhance molecular targeted therapies including immunotherapy.

Dr. Dicker is the author of four books and over 300 publications. His work has resulted in establishment of parameters for quality assurance in radiation oncology, novel therapeutic clinical trials utilizing targeted therapies, innovative models to evaluate radiation protectors and FDA approval of a genomic signature for management of prostate cancer.

Nationally, Dr. Dicker is Chair Emeritus, Integration Panel for the Prostate Cancer Research Program of the Department of Defense, Co-Chair of the Translational Science committee for NRG Oncology (www.nrgoncology.org) and the Radiation Oncology Co-Chair of the NCI Genitourinary Cancers Steering Committee Prostate Cancer Task Force. He is a member of the National Cancer Institute Investigational Drug Steering Committee (CTEP) and a consultant on Cancer to the European Commission, and the National Cancer Institute of Canada.

Since 1996, Dr. Dicker has mentored over 40 students, residents and fellows. This includes career development grants/awards, ASCO-AACR Vail Course applications, biweekly meetings with trainees, and long-distance video-conferencing. His trainees are early and mid-career clinician researchers and clinician-scientists in academic medicine in the US and abroad.

Deborah Estrin – Cornell University, New York, USA

Deborah Estrin is Associate Dean and Professor of Computer Science at Cornell Tech in New York City and a Professor of Public Health at Weill Cornell Medical College. She is founder of the Health Tech Hub and directs the Small Data Lab at Cornell Tech, which develops new personal data APIs and applications for individuals to harvest the small data traces they generate daily. Estrin is also co-founder of the non-profit startup, Open mHealth. Previously, Estrin was on the UCLA faculty where she was the Founding Director of the NSF Center for Embedded Networked Sensing (CENS), pioneering the development of mobile and wireless systems to collect and analyze real time data about the physical world and the people who occupy it.

Roozbeh Ghaffari – mc10, Lexington, USA

Dr. Roozbeh Ghaffari is co-Founder and Chief Technology Officer at MC10 Inc. In this role at MC10, Roozbeh has shaped the technology vision and is responsible for defining and developing emerging products. These efforts have led to the development and launch of the BioStamp® and epidermal bio-electronics as the foundation of MC10's product platform. Roozbeh’s contributions in soft bioelectronics, micro/nano-scale systems, and auditory neuroscience research have been recognized with the Helen Carr Peake PhD Research Prize, the MIT100K Grand Prize, the Harvard Business School Social Enterprise Grand Prize, and MIT Technology Review Magazine’s Top 35 Innovators Under 35. Roozbeh has published over 50 academic papers (including Nature Nanotechnology, Nature Materials, Nature Communications, and PNAS) and is inventor on over 60 patent applications and awards. Roozbeh holds B.S. and M.Eng degrees in electrical engineering from the Massachusetts Institute of Technology, and a Ph.D. in biomedical engineering from the Harvard-MIT Program in Health Sciences and Technology.

Joseph P. Giuffrida – Troofully, Hinckley, USA

Joseph P. Giuffrida, PhD, has expertise in medical technology, wearable sensors, and commercialization of software as a service for healthcare. Joe has commercialized multiple medical devices across several markets both in the United States and internationally. He successfully launched wearable sensor monitoring, cloud reporting, and mobile app technologies in the Parkinson’s disease and sleep markets, telemedicine in the respiratory therapy market, and developed strategies to restore motor control in spinal cord injury. Joe has significant experience leading product development and technical teams, implementing quality systems and regulatory requirements, building clinician support networks, and leading marketing and sales teams to grow and support product lines. His experience includes 13+ issued patents, 15+ clinical studies as principal investigator, and machine learning & algorithm development using sensor based networks with 50+ scientific publications. Joe received his PhD from Case Western Reserve University in 2004.

Jörg Goldhahn – ETH, Zurich, Switzerland

Prof Dr. med. Jörg Goldhahn works as the medical director of the new bachelor in medicine at the Swiss federal Institute of Technology (ETH) Zurich, Switzerland. He is also one of the founding members of the new Institute for Translational Medicine at ETH. One of his research interests is the quantification of medical need, especially in the musculoskeletal area. In the past, medical need has been quantified mainly via questionnaires. Recently wearables and sensor technology is the main focus of research. New technology enables continuous, remote monitoring, and adds new information. However, it requires systematic research abut chances but also limitations of the new technology.

Christian Gossens – Roche, Basel, Switzerland

Peter Groenen – Idorsia Pharmaceuticals, Allschwil, Switzerland

Peter Groenen currently heads the Translational Science Group at Idorsia Pharmaceuticals, a newly established company after the acquisition of Actelion Pharmaceuticals Ltd. by Johnson&Johnson. Having worked in academia and industry on multiple facets of disease he became fascinated by integrated approached using modern informatics and system approaches. He received his MSc in Biochemistry and Physiology from the Radboud University, Nijmegen the Netherlands. Before gaining his PhD in biomedical sciences at the Center for Human Genetics at the Gasthuisberg Medical Hospital, University of Leuven, Belgium he was a junior scientist at the National Institute for Health and Environmental Protection, Bilthoven the Netherlands and F. Hoffmann-La Roche AG, Basel Switzerland. Peter held several positions with increasing responsibility at Organon NV (part of Akzo Nobel), Schering-Plough and Merck Sharp & Dohme, Oss, the Netherlands. Peter Groenen has authored or co-authored over 30 peer reviewed articles in diverse areas of genetics, bioinformatics and biomarkers. He led two large national projects in the Netherlands on genomics and bioinformatics has been a member of several international consortia in biomarkers and pharmacogenomics.

Hossam Haick – Technion – Israel Institute of Technology, Haifa, Israel

Hossam Haick is a Full Professor in the Technion – Israel Institute of Technology and head of three major European consortia, has received numerous prestigious Prizes and Awards and was included in several important lists, including the list of the world’s 35 leading young scientists published by MIT’s Technology Review, the Nominet Trust 100 list (London), which includes the world’s 100 most influential inventors and digital developments, and the Los Angeles-based GOOD Magazine’s list of the 100 most influential people in the world. Highly multi-disciplinary in nature, the research of Prof. Haick combines knowledge from diverse fields, including nanotechnology, microfluidics, machine learning, biochemistry, medicine and genetics. Borrowing from these different disciplines, his research team develops novel solid-state and flexible devices/sensors as well as electronic sensory nanoarrays non-invasive diagnosis of diseases via volatile biomarkers. Prof. Haick’s comprehensive approach comprises materials and device development, system integration, testing in lab and clinical environments and exploitation of project results/hardware.

Dustin Heldman – Great Lakes NeuroTechnologies, Cleveland, USA

Dustin has expertise in neural engineering and neurophysiology, and has lead a biomedical team to develop and validate over 20 algorithms for quantifying movement disorder motor symptoms. He has been PI on 8 NIH programs totaling nearly $5 million and has managed over 15 multisite clinical trials. He has 4 issued US patents and has co-authored 15 peer-reviewed publications and 36 conference presentations.

M. Ehsan Hoque – University of Rochester, Rochester, USA

M. Ehsan Hoque is an assistant professor of computer science and an Asaro-Biggar (‘92) Family Fellow in Data Science at the University of Rochester, where he leads the Rochester Human-Computer Interaction (ROC HCI) Group. His group’s research focuses on understanding and modeling the unwritten rules of human communication, with applications in business communication, health, and educational assessment technology.
Ehsan earned his Ph.D. in the MIT Media Lab in 2013, where his dissertation was highlighted by the MIT Museum as one of the most unconventional inventions at MIT. Ehsan and his group’s work has earned them four Paper Awards and Best Paper Nominations at the premier Human-Computer Interaction conferences. Ehsan has received an MIT TR35 (2016), a World Technology Award (2016), and Science News 10 early- to mid-career scientists to watch (the “SN 10”).

Mohanraj Karunanithi – The Australian eHealth Research Centre, Herston, Australia

Mohanraj Karunanithi obtained his doctorate in Biomedical Engineering at the University of New South Wales. He has worked in cardiac research for 10 years on ventricular function. He has also gained experience working in medical industries (such as Agilent technologies and Philips Medical Systems) managing the engineering and customer service operation of cardiac and medical IT products in Asia Pacific region. He is currently a Group Leader at the AEHRC, CSIRO coordinating and directing research teams and scientists, and supervising students in the area of Integrated mobile and telehealth health applications in the management of chronic diseases and aged care. The research work includes a recent publication of the world’s first evidence based mobile health delivery of cardiac rehabilitation. He is a senior member of the largest biomedical engineering society, IEEE Engineering Medicine and Biology Society and is the founding and current chair of its chapter in Queensland, Australia.

Martin Kelly – HealthXL, Dublin, Ireland

Martin is Co-founder and CEO of HealthXL. Founded in 2014, HealthXL is an IBM spinout and has become the leading global platform for digital health evidence and innovation. HealthXL works with 25+ of the leading global health, life-science organisations who use the platform to find innovation, validate evidence and form partnerships with key opinion leaders. Previously, Martin was a Partner with IBM Venture Capital and was awarded the Global Corporate Venturing Personality Award in 2012. He is passionate about leadership, entrepreneurship, technology and collaboration to solve our biggest challenges. In addition Martin has served a number of advisory roles including: Advisory board member on the Innovation Fund Ireland, and Advisor to Science Gallery (inc. co-curator of Hack the City). He likes 60's soul, rugby and beers (but not at the same time).

Sean Khozin – US Food and Drug Administration, Silver Spring, USA

Dr. Khozin is Acting Associate Director at FDA’s Oncology Center of Excellence and the founder of Information Exchange and Data Transformation (INFORMED), an incubator for collaborative oncology regulatory science research focused on supporting innovations that enhance FDA’s mission of promotion and protection of the public’s health. Drawing from the expertise of a diverse group of oncologists, data scientists, statisticians, and entrepreneurs-in-residence, INFORMED is expanding organizational and technical infrastructure for big data analytics and examining modern approaches in evidence generation to support regulatory decisions. The research portfolio of INFORMED includes investigations into the use of real world data for clinical evidence generation and prospective pragmatic clinical trials, testing the utility of biosensors and the internet of things to quantify intrinsic and extrinsic (e.g., environmental) factors influencing the patient’s experience, identifying opportunities for machine learning and artificial intelligence to improve existing practices, and exploring the utility of emerging technologies such as blockchain to enable secure exchange of health data at scale.

Previously, Dr. Khozin was in private practice in New York City, an attending physician at St. Vincent’s Hospital in Manhattan, and an entrepreneur specializing in building health information technology systems with virtual patient management (including video, structured email, short message service and remote biometric monitoring) and point-of-care data visualization and analytics capabilities.

Dr. Khozin received his doctor of medicine degree from the University of Maryland School of Medicine and his master of public health from George Washington University. He completed internship and residency in internal medicine at the New York Medical College St. Vincent’s Hospital and completed medical oncology fellowship at the National Cancer Institute (NCI).

Deborah Kilpatrick – Evidation Health, San Mateo, USA

Deborah Kilpatrick, PhD is the CEO of Evidation Health, a technology company focused on quantifying health outcomes in the digital era of medicine using real life data from connected patients. The Evidation platform applies predictive analytics and machine learning to develop digital biomarkers across therapeutic areas that link patient behavior to health outcomes. Prior to this role, she served as the Chief Commercial Officer of genomic diagnostics company CardioDx. Earlier in her career, Deborah held multiple leadership roles at Guidant Corporation, including Research Fellow, Director of R&D, and Director of New Ventures in the Vascular Intervention Division. She serves on the Georgia Tech Advisory Board and is a Fellow of the American Institute of Medical and Biological Engineering. Deborah is a co-founder of the MedtechVision Conference, now held annually in Silicon Valley. She holds BS, MS and PhD degrees in mechanical engineering with a bioengineering focus from Georgia Tech.

Mary Liz McCurdy – Android & Google Play, Mountain View, USA

Mary Liz is passionate about improving the quality of people’s lives through accessible technology. As the Global Lead for Health & Fitness for Android and Google Play, she challenges developers to build high impact apps to improve everyone’s health, everywhere. She believes building seamless app experiences that deliver real user outcomes will drive mass market health improvements. Mary Liz has focused on ecosystem and partnership development across app and web for several years at Google. Outside of Google, she is a dedicated practitioner and coach of health & wellness. She is as former Stanford Track & Field studen-athlete, current high school girls track coach, and published meditation researcher and teacher. Follow her on twitter at @marylizmcc.

David J. Mitten – University of Rochester, Rochester, USA

David E. Newman-Toker – Johns Hopkins Medicine, Baltimore, USA

Dr. David E. Newman-Toker is an internationally-recognized leader in neuro-otology, acute stroke diagnosis, and the study of diagnostic errors. He completed his undergraduate studies at Yale University, his medical degree at University of Pennsylvania, his residency training at Harvard University, and his doctoral degree in clinical research methods at the Johns Hopkins Bloomberg School of Public Health.

He is Professor of Neurology, Otolaryngology, and Emergency Medicine at the Johns Hopkins University School of Medicine. He serves as Director of the Division of Neuro-Visual & Vestibular Disorders in the Department of Neurology and as Director of the Armstrong Institute Center for Diagnostic Excellence. He is a Core Faculty member in the Brain Injury Outcomes Clinical Trials Unit and Trial Innovation Center.

Dr. Newman-Toker’s clinical interest is in diagnosis of acute disorders affecting the brainstem and cranial nerves, particularly stroke. His research mission is to achieve better outcomes through better diagnosis. He has been the principal investigator for multiple NIH, AHRQ, and foundation grants. He has published more than 90 journal articles and given more than 170 invited lectures on dizziness and diagnostic errors. He is a founding member of the Society to Improve Diagnosis in Medicine (SIDM) and is active in the national movement to eliminate patient harms from diagnostic error. He currently serves on SIDM’s Board of Directors and as Chair of its Policy Committee. He currently sits on the National Quality Forum (NQF) expert panel developing national measures of diagnostic accuracy and error.

Larsson Omberg – Sage Bionetworks, Seattle, USA

As the Director of Systems Biology, Larsson Omberg oversees a research agenda that focuses both on genomics and participant centered research where data is being collected using remote sensors and mobile phones. The group focuses heavily on using open and team based science to get a large number of external partners to collaborate on data intensive problems. Dr. Omberg has a background in computational biology and has been developing computational methods for genomics analysis and disease modeling. Dr Omberg obtained a MSc in Engineering Physics from the Royal Institute of Technology in Stockholm Sweden and a PhD. from the University of Texas at Austin in Physics before performing a postdoctoral fellowship in Computational Biology and Biostatistics at Cornell University.

Michael Ong – UCLA David Geffen School of Medicine, Los Angeles, USA

Michael K. Ong, M.D., Ph.D. is an Associate Professor at the UCLA David Geffen School of Medicine in Los Angeles, California, and a staff physician at the Greater Los Angeles VA Health Care System where he is the research leader for its section of hospital medicine. His research interests focus on improving the delivery of appropriate and efficient health care by general internal medicine physicians. His research has applied this focus in several areas of general medicine, including health system-based care, mental health, and tobacco control. Dr. Ong is the Director for UCLA Connected Health, which facilitates all telemedicine, telehealth, and mHealth activities for the UCLA Health System.

8EB) p_Papapetropoulos
Spyros Papapetropoulos – Massachusetts General Hospital, Boston, USA

Spyros is a recognized researcher, an experienced biopharmaceutical and healthcare executive and a digital health pioneer. Spyros has held positions of increasing responsibility in biopharma, has filed multiple INDs and has overseen a wide spectrum of clinical development programs in various therapeutic areas leading to successful regulatory filings and new product launches. He has been a founding member and advisor to multiple digital health companies and has led efforts in developing and validating novel technology-based tools and solutions. Spyros is a board-certified Neurologist and holds appointments as Consultant with Massachusetts General Hospital and Voluntary Professor of Neurology with the University of Miami, Miller School of Medicine. He has authored impactful peer-reviewed publications, book chapters, presented and chaired meetings since 1998. Spyros is currently co-chairing the International Parkinson’s Disease and Movement Disorders Society’s (IPMDS) Taskforce on Technology and is a member of various US government and non-profit committees on healthcare and biomedical research innovation.

Ralf Reilmann – George-Huntington-Institute, Münster, Germany

Jane Rhodes – Biogen, Cambridge, USA

Jane Rhodes is Senior Director of New Initiatives for the Value Based Medicine team in the Biogen innovation hub. Dr Rhodes leads a number of initiatives that employ digital solutions to help transform multiple sclerosis patient care including the development of an i-Pad-based MS performance test for self-administered functional neurological assessment.

Dr Rhodes began her scientific career in the field of neurology drug discovery research, and worked on novel therapies for stroke, MS, ALS, Parkinson’s disease and Alzheimer’s disease, with a particular interest in the neuro-inflammatory components of these diseases. In this capacity, she published numerous peers reviewed papers and is named as an inventor on ten patents. After completing her MBA, Dr Rhodes led cross-functional teams working on products in all phases of drug development thorough commercialization and life cycle management.

Dr Rhodes earned her undergraduate Joint Honors degree in Pharmacology and Physiology from the University of Manchester, UK, and her PhD in Neurophysiology, also from the University of Manchester, UK. Dr Rhodes also holds a Masters in Business Administration from Babson College F.W. Olin School of Business, in Wellesley MA.

Carlos Rodarte – Volar Health, Cambridge, USA

Carlos Rodarte is the Founder & Managing Director of Volar Health, LLC — a operations-focused digital health consultancy that helps innovative health companies refine their product strategy and rapidly commercialize their solutions. Areas of expertise include digital biomarkers, digital therapeutics, consumer and clinical wearables, next-generation biosensors, and -omics technologies.

Previously, Carlos was co-founder & CEO of HealthRhythms, a AI-driven digital health startup utilizing smartphone sensors including light sensing, voice analysis and speech rate detection, and physical mobility patterns to better understand human behavior and mood anomalies. Beforehand, at PatientsLikeMe, the leading peer-to-peer research platform, he oversaw strategic partnerships with pharma and biotech, and developed the company’s wearables and biosensors capabilities. Importantly, he helped create a virtual research approach to help validate consumer wearables for research purposes.

Carlos is an active startup mentor, member of several advisory boards, and recognized speaker on health innovation, having spoken at notable venues such as Cleveland Clinic Medical Innovation Summit and more popular outlets such as Health 2.0. In 2015, Carlos was named a "40 under 40 Healthcare Innovator" by MedTech Boston and in 2016 a “Top 100 Digital Health Influencer” by Onalytica.

Jorge Rodriguez – Beth Israel Deaconess Medical Center, Boston, USA

Jorge A. Rodriguez is a hospitalist and Clinical Informatics fellow in the Division of Clinical Informatics at BIDMC whose research focuses on achieving digital health equity. His passion lies in the meaningful intersection of medicine, social justice, and technology. Jorge has presented his work revealing a new digital divide for limited English proficiency patients at local, regional, and national conferences. He was recently awarded the inaugural BIDMC UiM Fellow and Jr. Faculty Career Development Research Award. He continues to foster alliances with community stakeholders to use technology as a transformative tool for empowering underserved patients in their care.

For his undergraduate training, Jorge attended Brown University, where he majored in biochemistry. He also took his first computer science class at Brown, exposing him to the potential impact of technology. Jorge completed his medical training at Tufts University School of Medicine, where he participated in research exploring the human computer interaction. He recently finished residency in Internal Medicine at Massachusetts General Hospital, which provided critical insights into the clinical and social barriers many patients face in obtaining quality healthcare. His experiences as a resident also facilitated his keen understanding of how those barriers can be overcome with novel solutions.

Jorge was born in Cartagena, Colombia and immigrated to the US with his parents. He grew up in Queens, New York.

Leonard Sacks – US Food and Drug Administration, Silver Spring, USA

Leonard Sacks received his medical education in South Africa, moving to the USA in 1987, where he completed fellowships in immunopathology and Infectious Diseases. He worked as an attending physician in Washington DC and South Africa and he joined the FDA in 1998 as medical reviewer in the Office of New Drugs. Subsequent positions included acting director of the Office of Critical Path Programs and associate director for clinical methodology in the Office of Medical Policy in the Center for Drug Evaluation and Research. In this capacity he has led efforts to support the use of electronic technology in clinical drug development. Besides his involvement in the design and analysis of clinical trials, he maintains a special interest in tuberculosis and other tropical diseases and has published and presented extensively on these topics. He is board certified in Internal Medicine and Infectious Diseases and holds an academic appointment as Associate Clinical Professor of Medicine at George Washington University.

Amy Sheon – Case Western Reserve University School of Medicine, Cleveland, USA

Amy Sheon has, since 2011, served as the Founding Executive Director of the Urban Health Initiative at Case Western Reserve University School of Medicine. With a PhD in Health Management and Policy from Johns Hopkins University, her career-long focus has been on using multiple data sources to address health disparities. Prior work experience includes collection of Demographic and Health Surveys in Asia, Africa and the Caribbean; HIV vaccine and prevention trials at the National Institutes of Health, initiating large multicenter programs in clinical research and ethical issues in genetics at the University of Michigan, and co-Directing the Childhood Obesity Prevention Mission Project at the non-profit Altarum Institute. She founded and operates HealthDataMatters.org with hyperlocal data on health and determinants of health. Through Public Health Innovators, LLC, Sheon helps clients develop and use technology to address population health, community health, and wellness.

(EB) p_stem
Komathi Stem – monARC Bionetworks, Palo Alto, USA

Komathi is the Founder and CEO of monARC Bionetworks. As an entrepreneurial systems thinker, she is focused on sparking an ecosystem change that accelerates discovery through greater collaboration across clinical care and clinical research. She is currently leveraging digital technologies to empower patients and enable greater collaboration to exponentially transform clinical trials to be faster, more cost efficient and accessible to more patients. With over 25 years of biopharma experience from Genentech, AstraZeneca and Eli Lilly, she has built and led high impact field and global corporate teams with up to 500 employees across multiple headquarter sites and functions (commercial, clinical operations, regulatory and innovation). As a senior executive she has driven numerous large scale clinical trial transformation to deliver patient centric solutions. Komathi received her MS in Biomedical Engineering from University of Virginia and her BA in Mathematics from St. Olaf College.

Gabriel Vargas – Amgen Medical Sciences, San Francisco, USA

Gabriel obtained his undergraduate degree from the University of California at Berkeley where he majored in anthropology & genetics. He received his MD and PhD degrees from the University of California at Irvine and went on to complete a research track residency in Psychiatry at the University of California at San Francisco (UCSF). After both a clinical and research fellowship he was appointed an assistant professor in the Psychiatry Department at UCSF where he spent 3 years leading a research group.

After leaving academia in 2006 he spent five years at Roche the last 3 in Basel, Switzerland as head of the Neuroscience Biomarker Group where he worked on biomarkers including digital approaches. He joined Amgen in 2011 and leads a group of physician-scientists in Neuroscience and heads the Digital Health activities in Medical Sciences. He co-leads the Digital Innovation lab and has conducted several digital health studies to test wearable sensors and devices and patient engagement technologies.

(EB) p_wicks
Paul Wicks – PatientsLikeMe, Cambridge, USA

Paul Wicks, Ph.D., is Vice President of Innovation at PatientsLikeMe, an online community for people living with medical conditions. Specialising in the conduct of clinical research using the Internet, Paul is responsible for shaping the scientific validity of the PatientsLikeMe platform and generating insights from the personal health data shared by members. This sharing of online medical data has lead to over 95 novel studies including a patient-led observational trial of lithium in ALS, digital tools to develop patient-reported outcome measures, a “dose-response” curve for the benefits of friendship between patients, and new methods for gaining patient input into clinical trial design. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in rare forms of ALS, and the psychological consequences of Parkinson’s disease. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award and was recognized as a TED Fellow in 2012.

Sarah H. Ying – Shire, Lexington, USA

Sarah H. Ying is a board-certified neurologist who specializes in vestibular and balance disorders, with a particular interest in modeling clinically relevant human biology to guide therapeutic approaches in clinical care. She received her undergraduate degree in biochemical sciences from Harvard College and her medical degree from Johns Hopkins University. She stayed at Johns Hopkins for internal medicine internship and fellowship before heading to Washington University, St. Louis, for neurology residency. She then completed a combined research and clinical fellowship in neurotology and neuroimaging at UCLA before returning to Johns Hopkins Hospital for a combined research and clinical fellowship in neuroophthalmology. Now, she serves at Shire as a Global Clinical Development Lead in Neuroscience, Neurogenetic Products. Research interests include analysis of structure-function correlations in neurodegenerative disease, with a particular emphasis on quantitative approaches.